Please use this form for submitting your comments and share your completed comment form to JCA\_Secretariat@zinl.nl prior to the deadline (02 August 2022, 23:59 CET). When submitting your comment form, please include “EUnetHTA 21 – Public Consultation – D4.5, D4.6, D5.2’’ in the subject line of your e-mail.

Please carefully read the principles for public consultation [here](https://www.eunethta.eu/public-consultation/), prior to your review, as these are binding for our process.

We kindly ask you to:

1. Submit one consolidated response per organisation; in a word-file
	1. PDF files will not be accepted;
2. Complete the first table; if this table is not completed, the input will not be considered by EUnetHTA 21;
3. Put each new comment in a new row;
	1. Please be clear about the context of your comment and if possible, provide a suggestion for rewording;
	2. Please consider the [HTA Regulation (EU) 2021/2282](https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32021R2282) when reviewing the document and when you provide comments;
	3. Please consider the corresponding project plan when commenting. Comments that refer to matters out of the scope of the deliverable may not be considered by EUnetHTA 21.
	4. Please do not provide linguistic comments, as the document will undergo language editing prior to finalization;
4. Insert the page number and line/section number on which your comment applies. If your comment relates to the document as a whole, please put **‘general’** in this column;
5. Provide a description of your comment as specific as possible and preferably also provide a suggestion for rewording. If you wish to draw our attention to published literature, please supply the full reference;
6. Add rows as needed.

NB: All comments received within the deadline of the consultation and following the correct format will be published on the website, together with the final deliverable. Only comments eligible for consideration will be answered by EUnetHTA 21. The answers will be made publicly available as well. EUnetHTA 21 may decide to rank the comments received on importance.

**Please complete this table. If this is not completed, your comments will not be considered.**

|  |  |
| --- | --- |
| **Name organisation & abbreviation** |  |
| **Country** |  |
| **Contact details (name & e-mail address) *– this information will not be published***  |  |

| **Sub-deliverable** | **Comment from** | **Page number** | **Line/ section number** | **Comment and suggestion for rewording** | **Is your comment an editorial comment?** |
| --- | --- | --- | --- | --- | --- |
|  | ***Insert your name and organisation******Please repeat in each row*** | ***Insert***  ***‘general’ if it relates to the whole document*** ***Please don’t put ‘p’ before the number*** |  | ***Please insert each new comment in a new row.*** | ***Please indicate with ‘x’ if your comment is an editorial comment.*** |
| D4.5 onApplicability of evidence |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| D4.6 Validity of clinical studies |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| D5.1 Guidance on JCA Submission Dossier Template |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |